Literature DB >> 10738862

Dopamine D3 receptor variant and tardive dyskinesia.

M Rietschel1, H Krauss, D J Müller, T G Schulze, M Knapp, K Marwinski, A O Maroldt, S Paus, F Grünhage, P Propping, W Maier, T Held, M M Nöthen.   

Abstract

In the search for genetic factors contributing to tardive dyskinesia, dopamine receptor genes are considered major candidates. The dopamine D3 receptor is of primary interest as dopamine D3 receptor knock-out mice show locomotor hyperactivation resembling extrapyramidal side-effects of neuroleptic treatment. Furthermore, Steen and colleagues (1997) recently reported an association between tardive dyskinesia and a dopamine D3 receptor gene variant. In the present study we tried to replicate this finding. We investigated 157 patients with schizophrenia or schizoaffective disorder receiving long-term neuroleptic medication who never or persistently displayed tardive dyskinesia. As advanced age is a main risk factor for tardive dyskinesia, we also compared older patients with a long duration of schizophrenia not displaying tardive dyskinesia to younger patients with a shorter duration of the illness displaying tardive dyskinesia. However, we found no evidence that the dopamine D3 receptor gene is likely to confer susceptibility to the development of tardive dyskinesia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10738862     DOI: 10.1007/pl00007536

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  12 in total

Review 1.  Recent advances in the genetics of schizophrenia.

Authors:  D M Waterwort; A S Bassett; L M Brzustowicz
Journal:  Cell Mol Life Sci       Date:  2002-02       Impact factor: 9.261

Review 2.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01       Impact factor: 4.481

Review 3.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

4.  Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia.

Authors:  Daniel Farré; Ana Muñoz; Estefanía Moreno; Irene Reyes-Resina; Júlia Canet-Pons; Iria G Dopeso-Reyes; Alberto J Rico; Carme Lluís; Josefa Mallol; Gemma Navarro; Enric I Canela; Antonio Cortés; José L Labandeira-García; Vicent Casadó; José L Lanciego; Rafael Franco
Journal:  Mol Neurobiol       Date:  2014-10-26       Impact factor: 5.590

Review 5.  Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Authors:  Maria J Arranz; Margarita Rivera; Janet C Munro
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

Review 6.  Pharmacogenetics as a tool in the therapy of schizophrenia.

Authors:  Bob Wilffert; Rianne Zaal; Jacobus R B J Brouwers
Journal:  Pharm World Sci       Date:  2005-02

Review 7.  Genetic predictors of therapeutic response to clozapine: current status of research.

Authors:  Dalu Mancama; Maria J Arranz; Robert W Kerwin
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

8.  Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients.

Authors:  Ying-Jay Liou; Ding-Lieh Liao; Jen-Yeu Chen; Ying-Chieh Wang; Chao-Cheng Lin; Ya-Mei Bai; Shun-Chieh Yu; Ming-Wei Lin; I-Ching Lai
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

Review 9.  Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders.

Authors:  Florence Cf Chang; Victor Sc Fung
Journal:  Pharmgenomics Pers Med       Date:  2014-10-13

10.  Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for clinicians.

Authors:  Adriana Foster; Zixuan Wang; Manzoor Usman; Edna Stirewalt; Peter Buckley
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.